Valion Bio, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Valion Bio, Inc. (VBIO) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 40.82 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-14
- Valion Bio, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 28.29M shares, a 2527.48% increase year-over-year.
- Valion Bio, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 1.08M shares, a 15963.58% increase year-over-year.
- Valion Bio, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 6.70K shares, a 73.16% decline year-over-year.
- Valion Bio, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 24.97K shares, a 98.11% decline year-over-year.
- Valion Bio, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 20.18M shares, a 2717.38% increase from fiscal 2024.
- Valion Bio, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 716.10K shares, a 16313.06% increase from fiscal 2023.
- Valion Bio, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 4.36K shares, a 99.72% decline from fiscal 2022.
- Valion Bio, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 1.54M shares, a 9893.71% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 40.82M shares 10-Q · filed 2026-08-14 | |||||||
| 2026-03-31 | 28.29M shares 10-Q · filed 2026-05-14 | |||||||
| 2025-12-31 | 20.18M shares 10-K · filed 2026-03-30 | |||||||
| 2025-09-30 | 4.50M shares 10-Q · filed 2025-11-14 | |||||||
| 2025-06-30 | 1.08M shares 10-Q · filed 2026-08-14 | 1.42M shares 10-Q · filed 2025-08-14 | ||||||
| 2025-03-31 | 1.08M shares 10-Q · filed 2026-05-14 | |||||||
| 2024-12-31 | 716.10K shares 10-K · filed 2026-03-30 | |||||||
| 2024-09-30 | 711.14K shares 10-Q · filed 2025-11-14 | 12.09M shares 10-Q · filed 2024-11-14 | ||||||
| 2024-06-30 | 710.45K shares 10-Q · filed 2025-08-14 | 12.08M shares 10-Q · filed 2024-08-14 | ||||||
| 2024-03-31 | 6.70K shares 10-Q · filed 2025-05-15 | 113.87K shares 10-Q · filed 2024-05-15 | ||||||
| 2023-12-31 | 4.36K shares 10-K · filed 2025-03-21 | 74.16K shares 10-K · filed 2024-03-25 | ||||||
| 2023-09-30 | 74.70K shares 10-Q · filed 2024-11-14 | |||||||
| 2023-06-30 | 29.16K shares 10-Q · filed 2024-08-14 | 2.92M shares 10-Q · filed 2023-08-14 | ||||||
| 2023-03-31 | 24.97K shares 10-Q · filed 2024-05-15 | 2.50M shares 10-Q · filed 2023-05-15 | ||||||
| 2022-12-31 | 1.54M shares 10-K · filed 2023-03-31 | |||||||
| 2022-09-30 | 15.58K shares 10-Q · filed 2023-11-14 | 1.52M shares 10-Q · filed 2022-11-14 | ||||||
| 2022-06-30 | 1.56M shares 10-Q · filed 2023-08-14 | |||||||
| 2022-03-31 | 1.32M shares 10-Q · filed 2023-05-15 | |||||||
| 2021-12-31 | 15.43K shares 10-K · filed 2024-03-25 | 879.90K shares 10-K · filed 2023-03-31 | ||||||
| 2021-09-30 | 2.65M shares 10-Q · filed 2022-11-14 | |||||||
| 2021-06-30 | 2.99M shares 10-Q · filed 2022-08-15 | |||||||
| 2021-03-31 | 3.03M shares 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |